Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. Long-term ATTR-CM trial data show durable benefits ...
Caring for someone with ATTR amyloidosis can be physically and emotionally demanding. To reduce the chances of burnout, caregivers should also prioritize their own well-being. Factors such as ...
Three of the 4 patients with hereditary transthyretin amyloidosis (ATTR) and a negative bone scintigraphy had cardiac carbon-11-labeled Pittsburgh compound B uptake. Cardiomyopathy could be detected ...
A PubMed search through June 30, 2025 identified 10 eligible comparative studies, pooling 5203 patients and using random-effects modeling to estimate mortality and cardiovascular hospitalization risk ...
Researchers conducted a retrospective cohort study using data from the US Veterans Health Administration to quantify the time from HF diagnosis to ATTR-CM diagnosis and identify predictors of delays ...
For over a decade, Ruth has written for multiple outlets providing patient education, including Health. She has written for health student education companies, collaborating on an anatomy textbook ...
The burgeoning field of transthyretin amyloid cardiomyopathy (ATTR-CM), which spurred excitement over a potential $20 billion market, may have just revealed the first indication of a slowdown. For the ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...
ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...
Sleep problems are extremely common when you’re living with transthyretin amyloid cardiomyopathy (ATTR-CM). This heart condition involves misshapen transthyretin protein building up in your heart ...
Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate ...
The life expectancy for transthyretin (ATTR) amyloidosis varies from person to person. Your age, overall health, and primary symptoms all play a role. Transthyretin amyloidosis (ATTR) is a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results